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0022-0736/© 2016 Pusegment elevation myocardial infarction (STEMI), “Terminal QRS distortion” is considered as “Grade
III”. This evidence for most severe ischemia is associated with cardiovascular magnetic resonance
imaging (CMR) markers of myocardial damage in the subacute phase. Our aim was to assess whether
terminal QRS distortions on the initial electrocardiogram (ECG) is predictive for infarct size (IS) and left
ventricular ejection fraction (LVEF) at 4 months in anterior versus infarct locations.
Methods: Patient data of the HEBE, GIPS III and MAST, were pooled. ECGs of 411 STEMI
patients were classified as absence (Grade II) or presence (Grade III) of terminal QRS distortion
according to Sclarovsky-Birnbaum grading. CMR was performed at approximately 4 months and
included IS and LVEF.
Results: Grade III ischemia was present in 142 of 411 (35%) patients and was more frequently observed
with inferior STEMI (P = 0.01). In the total cohort and in anterior STEMI, no difference in LVEF or IS
was observed between the twoGrades.Whereas, in inferior STEMIGrade III was associatedwith a larger
IS (P b 0.01) and also, a trend towards a lower LVEF was observed (P = 0.09).
Conclusion: In inferior STEMI, terminal QRS distortion on the initial ECG is associated with a
larger IS at approximately 4 months, and can be used to identify a high-risk population in the acute
phase. Also, a Grade III was associated with a trend towards a lower LVEF.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords: Electrocardiography; QRS distortion; Myocardial infarction; Magnetic resonance imagingIntroduction
The introduction of primary percutaneous coronary
intervention (PPCI) has resulted in an improved survival in
ST-segment elevation myocardial infarct (STEMI) patients,
and has also resulted in smaller infarct size (IS), less
remodeling, less impaired LVEF and less heart failure [1,2].
Identifying markers that aid early risk-stratification inauthor at: Department of Cardiology, VU University
rdam, Amsterdam, The Netherlands.
r.nijveldt@cardiologie-vumc.nl
16/j.jelectrocard.2016.03.009
blished by Elsevier Inc. This is an open access article undSTEMI is critical to determine optimal treatment strategies
and to improve outcome. The electrocardiogram (ECG)
remains a cornerstone diagnostic modality in STEMI
patients and thus identifying a prognostic ECG marker as a
risk-stratifying tool is both feasible and clinically applicable.
In STEMI, changes in the terminal portion of the QRS during
only most severe ischemia have previously been described, and
are believed to be caused by prolongation of the electrical
conduction in the myocardium in the ischemic zone [3,4]. These
QRS changes, specifically absence or occurrence of terminal
QRS distortion, can be classified according to the to the “severityer the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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different criteria for application in the ECG leads revealing the
acute changes in anterior versus inferior STEMI locations: the
“disappearing S wave criterion” for anterior and the “small R
wave to ST ratio” for inferior STEMI. Although this grading
system was initially developed in the thrombolysis era, several
studies have shown its prognostic value in PPCI treated STEMI.
Grade III ischemia on initial ECG has been shown to be
associated with less myocardial salvage, more microvascular
obstruction (MVO), increased infarct size (IS) and 30-day
mortality [5–9]. Previous studies have assessed its predictive
value for Cardiovascular Magnetic Resonance imaging (CMR)
markers of myocardial infarction assessed in the subacute phase.
However, its predictive value on long term IS and left ventricular
ejection fraction (LVEF) has not yet been investigated.
The primary objective of the current study, is to assess
whether the severity of ischemia on initial ECG, as classified
by the SB ischemia grading system, can be used to predict
LVEF and IS at approximately 4 months on CMR, for
different infarct locations.Methods
Study population
For the current analysis patient data were pooled from
the previously published HEBE, GIPS III and MAST study
[10–14], which all performed CMR approximately 4 months
following infarction.
In brief, the HEBE trial was designed to assess the effect of
bone marrow cell therapy on cardiac improvement in STEMI
patients assessed with CMR. A total of 200 patients that were
successfully treated with PPCI between August 2005 and
April 2008, were included in a randomized, multi-center, open
trial with blinded evaluation of endpoints [10,11].
The GIPS III trial, was designed to determine whether
metformin treatment following STEMI in patients without
diabetes preserves LVEF at four months as assessed with
CMR. A total of 380 patients who underwent PPCI between
January 2011 and May 2013 at the University Medical
Center Groningen, the Netherlands, were enrolled [12,13].
In both the HEBE and GIPS III trial, the effects of treatment
on systolic myocardial function following STEMI were neutral.
The MAST study was a prospective observational cohort
study of 89 consecutive first STEMI patients who underwent
successful PPCI between 2006 and March 2008 at the
Maastricht University Medical Center, the Netherlands. The
principal investigator of the GIPS III, HEBE and MAST
study were approached and consented to collaborate in a
patient level pooled analysis. The requested data was
provided and they vouched for the correctness of the data.
All studies were conducted in accordance with the
Declaration of Helsinki and the study protocol was approved
by institutional review boards of the participating centers.
These studies included patients with a new ST elevation at
the J point in at least 2 contiguous leads of≥2 mm (0.2 mV)
in men or ≥1.5 mm (0.15 mV) in women in leads V2–V3
and/or of ≥1 mm (0.1 mV) in other contiguous chest leads
or the limb leads.For this post-hoc ECG and CMR analyses the following
additional in- and exclusion criteria were applied. Patients
were considered eligible if there was an available initial
pre-reperfusion ECGs (in-ambulance, in-hospital or at the
catheterization laboratory) and LVEF was assessed by CMR
imaging at follow-up. Additional exclusion criteria for this
analysis were: re-infarction prior to CMR imaging, inverted
terminal T-waves, intraventricular conduction delay ≥120
milliseconds QRS duration (left or right bundle branch
block), any ventricular rhythm, or a ventricular paced rhythm
on the initial pre-PPCI ECG.
ECG analysis
A standard 12-lead ECG was recorded at baseline prior to
PPCI, either in-ambulance or in-hospital at a paper speed of
25 mm/s and a sensitivity of 10 mm/mV.
ECGs were analyzed in a blinded fashion by observer
(M.H.) after having completed comparison of the initial 40
ECGs with an experienced observer (G.W.) on the SB
severity of ischemia grading system. In case of disagreement,
a consensus was reached by re-evaluating the ECGs.
The refined SB Ischemia grading system as previously
described by Billgren et al. was used to categorize patients
into either Grade II or Grade III ischemia [5].
In patients with inferior STEMI location indicated by
ST-segment elevation primarily in leads II, III and aVF,
Grade II was defined as a J point to R wave amplitude
ratio b 0.5 and Grade III when this ratio was≥0.5. Whereas,
in patients with anterior STEMI indicated primarily by
ST-elevation in leads V1, V2 and V3, Grade II was defined
as ST-elevation with an S wave below the isoelectric line and
Grade III when ST elevation was present without an S wave
below the isoelectric line.Cardiovascular
Magnetic Resonance Imaging acquisition and analysis
CMRwas performed on a 1.5 or 3-T clinical CMR-scanner
at 115 ± 15 days following PPCI. CMR imaging protocols for
all three studies have been published previously [10,12,14]. In
short, both cine and delayed contrast-enhanced CMR were
performed in all studies to assess LVEF and IS.
On the cine short-axis images endocardial and epicardial
contours were manually traced on short-axis cine, excluding
papillary muscles, in the end-diastolic and end-systolic phases
to determine end-diastolic volume (LVEDV, ml), end-systolic
volume (LVESV, ml) and LVEF(%). LVEDV and LVESV
were subsequently indexed for body-surface area.
Late gadolinium enhancement images were obtained 10–
15 min after administration of a gadolinium-based contrast
agent using an inversion-recovery, gradient-echo pulse
sequence, with slice position identical to the cine images.
Infarct location could subsequently be identified as hyper-
enhancement and outlined. Summation of the volumes per
slice of areas of hyperenhancement, allowed calculation of
absolute IS (grams) and as a percentage of LV mass (% LV).
In all studies, the CMR data were analyzed using a
dedicated software package and observers were blinded to
clinical data.
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Normally distributed data are expressed as mean ± SD
and for non-normal distributed data the median value
(Q1-Q3) is provided. Categorical variables are presented as
number (%) and compared using the chi-square test. A
Student's t- test or a 1-way analysis of variance was used to
compare data with a normal distribution of continuous
variables and a Mann–Whitney U test for non-normal
distributed continuous variables.
LVEF(%), IS (in grams and% LV), LVEDVindex (ml/m2)
and LVESVindex (ml/m2) were compared between patients
with Grade II and Grade III ischemia by using a Mann–
Whitney U test. This was assessed in the total STEMI study
population, anterior vs. inferior STEMI.Fig. 1. Grade II and III of ischemia in different infarct-related arteries. The patient i
artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronA P value b0.05 was considered statistically significant.
All statistical analysis were performed using SPSS software
(version 22.0; SPSS Inc., Chicago, Illinois).Results
In total 421 patients underwent CMR imaging at
follow-up and had a suitable pre-PPCI ECG (Fig. 1).
However, ten patients experienced a re-infarction prior to
CMR and were excluded. The current study thus included
411 patients. A severe Grade of ischemia (Grade III) was
identified in 142 (34.5%) patients, whereas 269 (65.5%)
patients had a Grade II ischemia. (See Fig. 2).n the LCX Grade II example had a dominant LCX artery.IRA, infarct related
ary artery; RCA, right coronary artery.
Fig. 2. Flowchart of included patients. STEMI, ST-elevation myocardial infarct; PPCI, primary percutaneous coronary intervention; re-MI, re-myocardia
infarction; CMR, cardiovascular magnetic resonance imaging; FU, follow-up; BBB, bundle branch block; ECG, electrocardiogram.
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and in the Grade II and Grade III groups are depicted in
Table 1. Mean age was 57 ± 11 years and the majority of the
included patients were male (80.5%). Grade III ischemia was
more frequently observed when the IRA was the right
coronary artery (RCA) (P = 0.01) and in the presence of
multivessel disease (P = 0.03). Whereas, Grade II ischemia
was more often observed when the left anterior descending
artery (LAD) was the IRA. Time from symptom onset to
PPCI did not differ between the Grade II and Grade III
ischemia (P = 0.21).
As for LVEF and IS, no difference was observed between
the two grades in the total STEMI population (Table 2). In a
sub-analysis of the different infarct locations, IS and LVEF
did not differ between the two Grades of ischemia in anterior
STEMI patients (Fig. 3). However in inferior STEMI, Grade
III ischemia was associated with a larger IS (P b 0.01). In the
inferior STEMI group, Grade III on the initial ECG was
associated with a larger IS at 4 months and a trend towards a
lower LVEF (Table 2).Discussion
To the best of our knowledge, the current study is the first
to assess whether the SB Grade of ischemia severity on
initial ECG can be used as an ECG marker for IS and LVEF
at 4 months following STEMI. We assessed the impact of the
Grade of ischemia for the entire cohort, and also according to
infarct location. The main finding of our analysis is that
terminal QRS distortion in Grade III on initial ECG can be
used as an ECG marker for IS at 4 months in inferior STEMIlpatients. This is a relevant finding considering that final IS
by CMR assessed 3 months following STEMI has been
shown to be an independent predictor for all-cause mortality
and admission for heart failure [15]. Also, a trend towards a
lower LVEF was observed in patients with a Grade III.
Whereas, the Grade of ischemia was not associated with IS
or LVEF at 4 months in anterior STEMI patients. In the total
STEMI population, no difference in IS and LVEF was
observed between both Grades of ischemia.
Several studies have investigated the association between
the severity of ischemia on initial ECG and IS on CMR
following STEMI [8,9,16,17]. However, in these studies
CMR was performed within one week and up to 10 days
following STEMI. In all studies Grade III ischemia was
associated with a larger IS, less myocardial salvage and more
microvascular obstruction.
In our study the severity of ischemia was not
associated with a different LVEF at follow-up in the total
STEMI population and in anterior STEMI, but was
predictive in inferior STEMI. These results are in accordance
with the study by Weaver et al., where an association was
observed between the Grade of ischemia and larger IS among
patients with inferior infarcts, but no association was found
in anterior STEMI patients [8] Several other studies on the
grade of ischemia and myocardium at risk have also reported
discrepant results on the association observed in different
IRA's and infarct locations. However, in another study that
included only anterior STEMI patients the severity of
ischemia was found to be independently associated with a
larger area at risk in anterior STEMI patients [16]. In the
study by Rommel et al., that included both anterior and
inferior STEMI patients, no difference in area at risk was
LVEF
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Total STEMI cohort
Inferior STEMI
Fig. 3. Left ventricular function and infarct size in total cohort and separate for anterior and inferior STEMI. IRA, infarct related artery; RCA, right coronary
artery; LCX, left circumflex artery; left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
IS, infarct size.
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no difference in LVEF measured within one week following
STEMI. These results from previous studies suggest that the
predictive value of the severity of ischemia may be different
with respect to infarct location. Infarct location has
previously been shown to be an independent predictor of
IS and left ventricular ejection fraction [18,19]. Moreover,
the criteria applied in the Sclarovsky-Birnbaum grading
system differ for anterior and non-anterior patients.
When considering the criteria used for anterior vs. inferior
STEMI, Grade III ischemia in anterior STEMI includes the
absence of S wave below the TPinferior-PR isoelectric line in
leads V1 to V3, whereas in inferior STEMI patients it is based
on the J point to R wave amplitude ratio. In inferior STEMI
patients it is questionable whether the criteria used for Grade II
and Grade III in these patients is an actual expression of severe
ischemia and not infarction. During ischemia the vector is
directed towards the ischemic area and in patients with a RCA
occlusion this would appear as an increased Rwave in leads II,
III and aVF. However, according to the Sclarovsky-Birnbaum
grading system patients with a Grade III ischemia have a
J-point to Rwave amplitude≥0.5 andmay be an expression of
infarction rather than ischemia.Whether the Grade of ischemia
in non-anterior patients is an actual marker of ischemia should
be further investigated.
This difference in definition between Grade II and Grade
III in anterior and inferior STEMI is the likely reason for the
discrepant results observed in infarct size at 4 months
between these infarct location groups. In patients with
inferior STEMI, SB Grade III is based on criteria that mostlikely represents a larger infarct size at the time of admission
ECG, and this difference persists after 4 months. However,
in anterior STEMI patients, the SB grading of ischemia is
based on criteria that most likely represent the severity of
ischemia, and therefore would not necessarily be related to
infarct size after 4 months. The final infarct size would be
expected to be minimalized only in the anterior STEMI
patients with a brief time to reperfusion, because of their
more rapid progression of ischemia to necrosis. However, in
the current study, since the median symptom onset to balloon
time was approximately 3 h (mean 2.8 h; SD 2.0–4.0), no
difference in final infarct size between those with initial
Grade II versus Grade III would be expected.
Nevertheless, in the current study the Grade of ischemia
holds a predictive value for assessing whether a patient will
have a large IS and decreased LVEF at 4 months in inferior
STEMI patients.
The advantage of the severity of ischemia grading is that
it is an ECG score that can easily be assessed in the acute
situation when important clinical decisions are being made.
Whether the Grade of ischemia can guide management in
clinical practice, such as in higher triage priority in countries
where there is a long ambulance-to-hospital time delay or the
use of adjunctive therapies, needs to be further investigated.Limitations
Several limitations should be mentioned. First, time to
reperfusion is an important variable in the ischemia-infarction
Table 1
Baseline characteristics.
Total study cohort (N = 411) Grade II ischemia (N = 269) Grade III ischemia (N = 142) P-value
Age (years) 57 ± 11 56 ± 11 58 ± 10 0.17
Male gender (%) 331 (80.5) 221 (82.2) 110 (77.5) 0.25
BMI (kg/m2)⁎ 26.1 (24.2–28.7) 26.2 (24.2–28.7) 26.0 (24.2–28.7) 0.85
Risk factors (%)
Diabetes mellitus 127 (30.9) 87 (32.3) 40 (28.2) 0.31
Current cigarette smoking 218 (53.0) 142 (52.8) 76 (53.5) 0.89
Hypertension 123 (29.9) 76 (28.3) 47 (33.1) 0.31
Dyslipidemia 185 (45.0) 116 (43.1) 69 (48.6) 0.18
Family history of CAD¥ 98/207 (47.3) 57/130 (43.8) 41/77 (53.2) 0.19
Previous PCI at baseline 6 (1.5) 3 (1.1) 3 (2.1) 0.49
Angiography and infarct treatment
Time symptom onset to PCI (h) 2.8 (2.0–4.0) 2.8 (2.0–4.2) 2.8 (1.9–3.7) 0.34
Infarct-related artery (%)
Left anterior descending artery 190 (46.2) 136 (50.6) 54 (38.0) 0.02
Left circumflex artery 56 (13.6) 37 (13.8) 19 (13.4) 0.92
Right coronary artery 165 (40.1) 96 (35.7) 69 (48.6) 0.01
Multivessel disease (%) 122 (29.7) 70 (26.0) 52 (36.6) 0.03
TIMI flow Grade pre-PCI
0 259 (63.0) 168 (62.5) 91 (64.1) 0.75
1 41 (10.0) 28 (10.4) 13 (9.2) 0.69
2 59 (14.4) 33 (12.3) 26 (18.3) 0.10
3 51 (12.4) 39 (14.5) 12 (8.5) 0.08
TIMI flow Grade post-PCI
2 27 (6.6) 21 (7.8) 6 (4.2) 0.16
3 383 (93.2) 247 (91.8) 136 (95.8) 0.13
Medication at discharge (%)
Salicylates 401 (97.6) 262 (97.4) 139 (97.9) 0.93
Clopidogrel 351 (85.4) 223 (82.9) 128 (90.1) 0.06
Ticagrelor 56 (13.6) 43 (16.0) 13 (9.2) 0.02
Prasugrel 1 (0.2) 1 (0.4) 0 (0) 0.45
Coumarine 26 (6.3) 15 (5.6) 11 (7.7) 0.40
Beta-blockers 396 (96.4) 256 (95.2) 140 (98.6) 0.10
ACE-inhibitor or AT II receptor blocker 349 (84.9) 223 (82.9) 126 (88.7) 0.14
Statins 408 (99.3) 266 (98.9) 142 (100) 0.30
BMI, body mass index; CAD, coronary artery disease; PCI, percutaneous coronary intervention; h, hours; TIMI, Thrombolysis in Myocardial Infarction;
ACE-inhibitor, angiotension converting enzyme inhibitor; AT II receptor blocker, angiotensine II receptor antagonist.
⁎ Missing in 204 patients. In GIPS study family history of coronary artery disease was not reported.
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the time symptom onset to PCI did not differ between Grade II
and Grade III ischemia (P = 0.21; Table 1). Recent other
studies have also observed no difference in symptom to
balloon time between the two Grades of ischemia.
Second, the recruitment period differs between the three
studies and treatment post STEMI may be different.
Although the HEBE and MAST study overlap in recruitment
period (2006–2008), the recruitment of GIPS III study was
from 2011 to 2013. The difference in ticagrelor use at
discharge between Grade II and Grade III ischemia groups is
the result of patients included in the GIPS III study. However
this would not have any influence on LVEF and IS.
Finally, in the current study we only included patients that
underwent CMR at 4 months and therefore cannot rule out
selection bias. Also, this analysis does not include STEMI
equivalents. This could have also caused a potential selection
bias in the results since it is possible that only patients with
large ischemia vectors (associated with larger ischemic areas
and potentially larger infarct sizes) were included. Further
research is needed to assess the relationship between
terminal QRS distortion on initial ECG and final infarct
size in these patients.Conclusions
The Grade of ischemia is an rapidly and easily ECG
marker predictive for IS and LVEF at 4 months in inferior
STEMI patients. Also, a trend towards a lower LVEF was
observed in inferior STEMI patients with a Grade III
ischemia. The severity of ischemia can identify a high-risk
patient population in the acute phase of STEMI and may aid
in clinical management.Acknowledgements
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Table 2
Left ventricular function and infarct size at 4 months.
Total study cohort Grade II Grade III P-value
All STEMI n = 411 n = 269 n = 142
LVEF (%) 53 (47–58) 53 (48–58) 53 (45–58) 0.70
LVEDV index (ml/m2) 94 (84–106) 94 (84–107) 93 (84–106) 0.42
LVESV index (ml/m2) 43 (35–55) 44 (36–55) 42 (34–56) 0.51
IS (grams) 10 (4–17) 10 (4–18) 11 (6–16) 0.36
IS (% LV)¥ 0.3 (0.1–10.8) 0.3 (0.1–9.4) 1.7 (0.1–11.3) 0.15
Anterior STEMI n = 190 n = 136 n = 54
LVEF (%) 51 (43–57) 50 (43–56) 51 (42–58) 0.81
LVEDV index (ml/m2) 100 (87–111) 101 (88–111) 97 (86–112) 0.76
LVESV index (ml/m2) 49 (38–61) 50 (39–61) 46 (35–64) 0.57
IS (grams) 14 (6–21) 14 (5–22) 15 (6–19) 0.49
IS (% LV) 2.6 (0.1–14.2) 2.6 (0.1–14.2) 3.6 (0.1–13.8) 0.54
Inferior STEMI n = 221 n = 133 n = 88
LVEF (%) 55 (50–59) 55 (52–60) 55 (48–59) 0.09
LVEDV index (ml/m2) 91 (80–102) 91 (81–101) 91 (77–102) 0.95
LVESV index (ml/m2) 41 (34–48) 41 (34–48) 41 (33–49) 0.54
IS (grams) 9 (4–13) 7 (3–11) 10 (5–14) b0.01
IS (% LV) 0.2 (0.1–8.0) 0.1 (0–6.6) 1.3 (0.1–9.9) b0.01
⁎Infarct size (gram) missing in 32 patients, including 26 in Grade II and in 6 in Grade III. Reported in Median (25th- 75th Percentile).
¥Infarct size (% LV) missing in 35 patients, of which 29 in Grade II and in 6 in Grade III.
STEMI, ST-elevation myocardial infarction; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular
end-systolic volume; IS, infarct size.
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